<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01892254</url>
  </required_header>
  <id_info>
    <org_study_id>PCOS-INK</org_study_id>
    <nct_id>NCT01892254</nct_id>
  </id_info>
  <brief_title>Incretin Effect in PCOS Women</brief_title>
  <official_title>Inkretineffekten Hos Patienter Med Polycystisk Ovariesyndrom f√∏r og Efter Behandling af Insulinresistens (Incretin Effect in Patients With Polycystic Ovary Syndrome Before and After Treatment of Insulin Resistance)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the incretin effect in women with polycystic ovary syndrome (PCOS)
      before and after removal of their insulin resistance by metformin.

      The investigators' hypothesis is that insulin resistant women with PCOS have a reduced
      incretin effect and elevated glucagon responses as measured by a 75-g oral glucose tolerance
      test and isoglycemic i.v. glucose infusion. The investigators hypothesise that both can be
      improved when their insulin resistance is removed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">November 23, 2017</completion_date>
  <primary_completion_date type="Actual">November 23, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in incretin effect from baseline and until after removal of insulin resistance</measure>
    <time_frame>baseline and 12 weeks' treatment</time_frame>
    <description>The incretin effect will be assessed from the insulin secretion during af 75 g OGTT and IIGI at baseline and after 12 weeks' treatment with placebo and metformin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucagon response</measure>
    <time_frame>0, 12 and 30 weeks</time_frame>
    <description>Glucagon responses (plasma concentrations) will be assessed during the 75-g OGTTs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Metformin-Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin, 2x 2 tablets a day, 500 mg tablets for 12 weeks, 6 weeks wash-out, 12 weeks placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-metformin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets, 2x 2 tablets per day for 12 weeks, 6 weeks wash-out, 12 weeks metformin, 2x 2 tablets per day, 500 mg per tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin, 2x 2 tablets a day, 500 mg tablets</description>
    <arm_group_label>Metformin-Placebo</arm_group_label>
    <arm_group_label>Placebo-metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (to metformin)</description>
    <arm_group_label>Metformin-Placebo</arm_group_label>
    <arm_group_label>Placebo-metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria PCOS-women:

          -  Diagnosed with PCOS according to the Rotterdam criteria

          -  more than 18 years old

          -  BMI less than 30 kg/m2

          -  Normal glucose tolerance and fasting plasma glucose (assessed by 75-g OGTT)

          -  Negative GAD65 and islet cell autoantibodies

          -  Insulin resistant according to HOMA-IR

          -  informed consent

        Inclusion Criteria healthy women:

          -  more than 18 years old

          -  BMI less than 30 kg/m2

          -  Normal glucose tolerance and fasting plasma glucose (assessed by 75-g OGTT)

          -  Negative GAD65 and islet cell autoantibodies

          -  informed consent

          -  regular menstrual cycle (28-35 days)

          -  Plasma androgen levels within reference levels

        Exclusion Criteria PCOS and healthy women:

          -  First or second degree relatives with diabetes

          -  pregnancy or breast feeding

          -  treatment with medication which influences the glucose metabolism (incl hormonal
             contraception)

          -  Congenital diseases which cause hyperandrogenism and irregular bleeding

          -  Known adrenal hyperplasia

          -  Known hyperprolaktinemia

          -  Alcohol consumption of more than 20 grams a day

          -  Hemoglobin less than 7.8 %
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louise Vedtofte, Cand.scient., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Copenhagen University Hospital, Gentofte</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Copenhagen University Hospital Gentofte</name>
      <address>
        <city>Hellerup</city>
        <state>Select A State</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2013</study_first_submitted>
  <study_first_submitted_qc>June 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2013</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Louise Vedtofte</investigator_full_name>
    <investigator_title>Humanbiolog, ph.d.</investigator_title>
  </responsible_party>
  <keyword>incretin effect</keyword>
  <keyword>PCOS</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>OGTT</keyword>
  <keyword>IIGI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

